Tuyet Pham, MD
Sleep Medicine · Dallas, TXNPI 1508396011
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,888 of the $3,866 with a category attached, or 74.7%. 19 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 39.0% of the total. 2025 is the largest year on record at $1,496, 2.7 times the $553 reported in 2019.
Across 78 payments — averaging $49.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- Novo Nordisk$810
- Lilly USA, LLC$222
- ZOLL Respicardia, Inc.$189
- AstraZeneca$187
- Dexcom, Inc.$176
- plus $773 from 13 others
What the payments were for
- Travel & lodging$93324%
- Food & beverage$2,88875%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 11 | $1,509 |
| Novo Nordisk | 28 | $810 |
| Lilly USA, LLC | 4 | $222 |
| ZOLL Respicardia, Inc. | 2 | $189 |
| AstraZeneca | 7 | $187 |
| Dexcom, Inc. | 2 | $176 |
| Abbott | 1 | $133 |
| Intuity Medical Inc | 1 | $116 |
| Gilead | 1 | $115 |
| GSK | 7 | $107 |
| Amgen | 3 | $63 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Harmony Biosciences LLC | 1 | $45 |
| Dynavax Technologies Corporation | 2 | $43 |
| Amarin Pharma, Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Organon | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,866 in reported general payments places this provider in the 70th percentile of 112 sleep medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 40 | $457 |
| Losartan Potassium | 20 | $217 |
| Levothyroxine Sodium | 14 | $135 |
| Lisinopril | 12 | $111 |
| Rosuvastatin Calcium | 11 | $76 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in Dallas
- John DebusDallas$38K
- Aaron PierceDallas$6K
- Nabeel FarahDallas$6K
- Andrew JamiesonDallas$5K
- Jack GardnerDallas$5K
- Sejal JainDallas$2K
- Rupini AllaDallas$2K
- Katie TranDallas$2K
- Arunkumar BadiDallas$1K
- Gerard MeskillSugar Land$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.